This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:diseases:hypertension [01.04.2019] – [Inflammation and Hypertension] sallieq | home:diseases:hypertension [01.04.2019] – [Notes and comments] sallieq | ||
---|---|---|---|
Line 63: | Line 63: | ||
- | In this review we summarize the recent evidence that highlights the involvement of low-grade inflammation in the development and pathophysiology of hypertension. | + | < |
RECENT FINDINGS: Essential hypertension is characterized by increased peripheral vascular resistance to blood flow, due in large part to vascular remodeling. Vascular changes in hypertension are associated with mechanical and humoral factors that modulate signaling events, resulting in abnormal function, media growth, extracellular matrix deposition and inflammation. Recent evidence suggests that inflammation is present in the vasculature in animal models of hypertension. Inflammatory markers, such as C-reactive protein, are associated with vascular lesions in humans, and are predictive of cardiovascular outcome. In animal and human studies, pro-inflammatory components of the renin-angiotensin-aldosterone system have been demonstrated in large conduit and small arteries in the kidney and heart. Peroxisome proliferator-activated receptor activators are drugs with metabolic properties that have been demonstrated to exert anti-inflammatory effects on the vasculature, | RECENT FINDINGS: Essential hypertension is characterized by increased peripheral vascular resistance to blood flow, due in large part to vascular remodeling. Vascular changes in hypertension are associated with mechanical and humoral factors that modulate signaling events, resulting in abnormal function, media growth, extracellular matrix deposition and inflammation. Recent evidence suggests that inflammation is present in the vasculature in animal models of hypertension. Inflammatory markers, such as C-reactive protein, are associated with vascular lesions in humans, and are predictive of cardiovascular outcome. In animal and human studies, pro-inflammatory components of the renin-angiotensin-aldosterone system have been demonstrated in large conduit and small arteries in the kidney and heart. Peroxisome proliferator-activated receptor activators are drugs with metabolic properties that have been demonstrated to exert anti-inflammatory effects on the vasculature, | ||
- | SUMMARY: Inflammatory processes are important participants in the pathophysiology of hypertension and cardiovascular disease. The identification of the mechanisms leading to the activation of inflammation should contribute to the development of specific therapeutic approaches to apply in hypertension and its complications. | + | SUMMARY: Inflammatory processes are important participants in the pathophysiology of hypertension and cardiovascular disease. The identification of the mechanisms leading to the activation of inflammation should contribute to the development of specific therapeutic approaches to apply in hypertension and its complications. |
//see also// | //see also// | ||
Line 77: | Line 77: | ||
Wilke, R. A., R. U. Simpson, et al. (2009). " | Wilke, R. A., R. U. Simpson, et al. (2009). " | ||
+ | < | ||
AIMS: We tested the hypothesis that genetic variation in vitamin D-dependent signaling is associated with congestive heart failure in human subjects with hypertension. MATERIALS & METHODS: Functional polymorphisms were selected from five candidate genes: CYP27B1, CYP24A1, VDR, REN and ACE. Using the Marshfield Clinic Personalized Medicine Research Project, we genotyped 205 subjects with hypertension and congestive heart failure, 206 subjects with hypertension alone and 206 controls (frequency matched by age and gender). | AIMS: We tested the hypothesis that genetic variation in vitamin D-dependent signaling is associated with congestive heart failure in human subjects with hypertension. MATERIALS & METHODS: Functional polymorphisms were selected from five candidate genes: CYP27B1, CYP24A1, VDR, REN and ACE. Using the Marshfield Clinic Personalized Medicine Research Project, we genotyped 205 subjects with hypertension and congestive heart failure, 206 subjects with hypertension alone and 206 controls (frequency matched by age and gender). | ||
Line 86: | Line 86: | ||
- | For some, the absence of well-defined causal connections between diseases and surrogate outcomes is a tribute to how truly complicated chronic inflammatory diseases are. Ralph B D' | + | For some, the absence of well-defined causal connections between diseases and surrogate outcomes is a tribute to how truly complicated chronic inflammatory diseases are. Ralph B D' |
__ | __ | ||
Line 101: | Line 101: | ||
- | [[http:// | ||
- | Remodeling | ||
- | Metabolic | ||
===== Members' | ===== Members' | ||
Line 126: | Line 123: | ||
//BROKEN LINK// [[http:// | //BROKEN LINK// [[http:// | ||
- | link to current research by 2 authoers | + | ANOR //DEAD LINK// |
+ | [[http:// | ||
+ | Remodeling | ||
+ | Metabolic | ||
+ | |||
+ | link to current research by 2 authers | ||
Vitamins | Vitamins | ||
Line 167: | Line 169: | ||
< | < | ||
- | http:// | + | http:// |
CONCLUSION: The administration of olmesartan improved blood pressure, insulin, HOMA, visfatin and lipid profile in hypertensive obese women. Irbesartan improved blood pressure and lipid levels. | CONCLUSION: The administration of olmesartan improved blood pressure, insulin, HOMA, visfatin and lipid profile in hypertensive obese women. Irbesartan improved blood pressure and lipid levels. | ||
Line 180: | Line 182: | ||
~~~~ | ~~~~ | ||
+ | (part below ref. USED on page --- --- //Sallie Q 01.04.2019// | ||
Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients. (({{pubmed> | Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients. (({{pubmed> | ||
Line 231: | Line 233: | ||
PMID: | PMID: | ||
- | 21504378</ | + | 21504378 |